

DAFTAR PUSTAKA

1. GLOBOCAN [Internet]. Global Cancer Observatory. [cited 2022Dec4]. Available from: <https://gco.iarc.fr/today/online-analysis-multi-bars>.
2. Kementerian Kesehatan RI [Internet]. Kementerian Kesehatan Republik Indonesia. [cited 2022Dec4]. Available from: <https://www.kemkes.go.id/article/view/22020400002/kanker-payudara-paling-banyak-di-indonesia-kemenkes-targetkan-pemerataan-layanan-kesehatan.html>
3. Yin L, Duan J-J, Bian X-W, Yu S-cang. Triple-negative breast cancer molecular subtyping and treatment progress. *Breast Cancer Research*. 2020;22(1).
4. Goldhirsch A, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. *Annals Oncol*. 2013;24(9):2206–2223.
5. Howard FM, Olopade OI. Epidemiology of Triple-Negative Breast Cancer: A Review. *Cancer J*. 2021 Jan-Feb 01;27(1):8-16.
6. Wu Q, Siddharth S, Sharma D. Triple Negative Breast Cancer: A Mountain Yet to Be Scaled Despite the Triumphs. *Cancers (Basel)*. 2021 Jul 23;13(15):3697.
7. Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. *Breast Cancer Research*. 2020 Jun 9;22(1):61.
8. Chaudhary LN, Wilkinson KH, Kong A. Triple-negative breast cancer: who should receive neoadjuvant chemotherapy? *Surgical Oncology Clinics of North America*. 2018;27(1):141–153.
9. Collignon J. Triple-negative breast cancer: treatment challenges and solutions. *Breast Cancer (Dove Med Press)* 2016;8:93–107.
10. Deputi Bidang Koordinasi Sumber Daya Maritim. Laporan Kinerja 2020. Indonesia: **Kementerian Koordinator Bidang Kemaritiman dan Investasi**. 2020.
11. Cirino P, Brunet C, Ciaravolo M. The Sea Urchin *Arbacia lixula*: A Novel Natural Source of Astaxanthin. *Marine Drugs*. 2017;15(6):187.
12. Nekvapil F , Brežeštan I , Tomšić S , Müller C , Chiş V , Cintă Pinzaru S . Microsphere packages of carotenoids: intact sea urchin eggs tracked by Raman spectroscopy tools. *Photochemical Photobiology Science*. 2019 Aug 1;18(8):1933-1944.
13. McCall B, McPartland CK, Moore R, Frank-Kamenetskii A, Booth BW. Effects of Astaxanthin on the Proliferation and Migration of Breast Cancer Cells In Vitro. *Antioxidants (Basel)*. 2018;7(10):135
14. Luparello C, Ragona D, Asaro DML, Lazzara V, Affranchi F, Arizza V, Vazzana M. Cell-Free Coelomic Fluid Extracts of the Sea Urchin *Arbacia lixula* Impair Mitochondrial Potential and Cell Cycle Distribution and Stimulate Reactive Oxygen Species Production and Autophagic Activity in Triple-Negative MDA-MB231 Breast Cancer Cells. *Journal of Marine Science and Engineering*. 2020; 8(4):261.
15. Paul SM, Mytelka DS, Dunwiddie CT. How to improve R&D productivity: the pharmaceutical industry's grand challenge. *Nature Reviews Drug Discovery*. 2013;9(3):203-214.

16. Giri S, Bader A. A low-cost, high-quality new drug discovery process using patient-derived induced pluripotent stem cells. *Drug Discovery Today*. 2015;20(1):37-49.
17. Moreno-García DM, Salas-Rojas M, Fernández-Martínez E, et al. Sea urchins: an update on their pharmacological properties. *PeerJ*. 2022;10:e13606.
18. Dona R, Frimayanti N, Ikhtiarudin I, Iskandar B, Maulana F, Silalahi NT. Studi in silico, Sintesis, Dan Uji Sitotoksik Senyawa P-Metoksi Kalkon Terhadap Sel Kanker Payudara MCF-7. *Jurnal Sains Farmasi & Klinis*. 2019;6(3):243.
19. Ensenyat-Mendez M, Llinàs-Arias P, Orozco JIJ, et al. Current Triple-Negative Breast Cancer Subtypes: Dissecting the Most Aggressive Form of Breast Cancer. *Front Oncology*. 2021;11:681476.
20. Tsai J, Bertoni D, Hernandez-Boussard T, Telli ML, Wapnir IL. Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer. *Annals of Surgical Oncology*. 2016;23(10):3310-3316.
21. Chen H, Wu J, Zhang Z, Tang Y, Li X, Liu S, Cao S, Li X. Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis. *Front Pharmacology*. 2018 Aug 21;9:909.
22. Newton EE, Mueller LE, Treadwell SM, Morris CA, Machado HL. Molecular Targets of Triple-Negative Breast Cancer: Where Do We Stand? *Cancers (Basel)*. 2022 Jan 18;14(3):482.
23. Tutt A, Ashworth A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. *Trends in Molecular Medicine*. 2013;8(12):571-576.
24. Mani S, Hande A, Boichuk S. Triple-negative breast cancer: The current aspects of pathogenesis and therapies. *BioNanoScience*. 2022;12(4):1404–35.
25. Zhang J, Dai J, Zheng Q. The Fluoro-Thiazolyldiazone Compound TSC-3C Inhibits Triple Negative Breast Cancer (TNBC) Cell Line Activity by Promoting Apoptosis, Regulating the MAPK Pathway and Inducing Mitochondrial Dysfunction. *International Journal of Molecular Sciences*. 2020;21(3):1038
26. Acosta-Casique A, Montes-Alvarado JB, Barragán M, Larrauri-Rodríguez KA, Perez-Gonzalez A, et al. ERK activation modulates invasiveness and Reactive Oxygen Species (ROS) production in triple negative breast cancer cell lines. *Cell Signal*. 2023 Jan;101:110487.
27. Jiang W, Wang X, Zhang C, Xue L, Yang L. Expression and clinical significance of MAPK and EGFR in triple-negative breast cancer. *Oncology Letters*. 2020 Mar;19(3):1842-1848.
28. Huang J, Luo Q, Xiao Y, Li H, Kong L, Ren G. The implication from RAS/RAF/ERK signaling pathway increased activation in epirubicin treated triple negative breast cancer. *Oncotarget*. 2017;8(64):108249-108260.
29. Wang W, Han D, Cai Q, Shen T, Dong B, Lewis MT, et al. MAPK4 promotes triple negative breast cancer growth and reduces tumor sensitivity to PI3K blockade. *Nature Communications*. 2022;13(1).
30. Massihnia D, Galvano A, Fanale D, et al. Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway. *Oncotarget*. 2016;7(37):60712-60722.

31. Zhu X, Zhou W. The Emerging Regulation of VEGFR-2 in Triple-Negative Breast Cancer. *Front Endocrinol (Lausanne)*. 2015 Oct 9;6:159.
32. Pascual J, Turner NC. Targeting the PI3-kinase pathway in triple-negative breast cancer. *Annals Oncology*. 2019;30(7):1051-1060.
33. Wahba HA, El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer. *Cancer Biology Medicine*. 2015 Jun;12(2):106-16.
34. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 8.2021 – September 13, 2021. Accessed November 19, 2021. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
35. Types of breast cancer: About breast cancer [Internet]. American Cancer Society. [cited 2022Dec4]. Available from: <https://www.cancer.org/cancer/breast-cancer/about/types-of-breast-cancer.html>
36. *Arbacia lixula* [Internet]. *Arbacia lixula*, Black sea urchin. [cited 2022Dec4]. Available from: <https://www.sealifebase.ca/summary/Arbacia-lixula.html>
37. *Arbacia Lixula* [Internet]. description of *Arbacia lixula* - Black sea urchin. [cited 2022Dec4]. Available from: <http://www.european-marine-life.org/30/arbacia-lixula.php?photo=0>
38. *Arbacia lixula* [Internet]. Worms - world register of marine species - *arbacia lixula* (Linnaeus, 1758). [cited 2022Dec4]. Available from: <http://www.marine-especies.org/aphia.php?p=taxdetails&id=124249>
39. Cirino P, Brunet C, Ciaravolo M, et al. The Sea Urchin *Arbacia lixula*: A Novel Natural Source of Astaxanthin. *Marine Drugs*. 2017;15(6):187.
40. Pilbrow J, Sabherwal M, Garama D, Carne A. A novel fatty acid-binding protein-like carotenoid-binding protein from the gonad of the New Zealand sea urchin. *PLoS One*. 2014 Sep 5;9(9):e106465.
41. Luparello C, Ragona D, Asaro DML, Lazzara V, Affranchi F, Arizza V, et al. Cell-Free Coelomic Fluid Extracts of the Sea Urchin *Arbacia lixula* Impair Mitochondrial Potential and Cell Cycle Distribution and Stimulate Reactive Oxygen Species Production and Autophagic Activity in Triple-Negative MDA-MB231 Breast Cancer Cells. *Journal of Marine Science and Engineering*. 2020; 8(4):261.
42. Widyananda MH, Pratama SK, Samoedra RS, Sari FN, Kharisma VD, Ansori AN, et al. Molecular docking study of sea urchin (*arbacia lixula*) peptides as multi-target inhibitor for non-small cell lung cancer (NSCLC) Associated Proteins. *Journal of Pharmacy & Pharmacognosy Research*. 2021;9(4):484–96.
43. Can T. Introduction to bioinformatics. *Methods Mol Biol*. 2014;1107:51-71.
44. Bayat A. Science, medicine, and the future: Bioinformatics. *BMJ*. 2012;324(7344):1018-1022.
45. Barh D, Chaitankar V, Yiannakopoulou EC, et al. In Silico Models: From Simple Networks to Complex Diseases. *Animal Biotechnology*. 2014;385-404.
46. Berry M, Fielding B, Gamiieldien J. Practical Considerations in Virtual Screening and Molecular Docking. *Emerging Trends in Computational Biology, Bioinformatics, and Systems Biology*. 2015;487-502.
47. Pohl SG, Brook N, Agostino M, Arfuso F, Kumar AP, Dharmarajan A. Wnt signaling in triple-negative breast cancer. *Oncogenesis*. 2017;6(4):e310.

48. Chatterjee S, Heukamp LC, Siobal M, et al. Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. *The Journal of Clinical Investigation*. 2013;123(4):1732-1740.
49. Shibuya M. VEGF-VEGFR Signals in Health and Disease. *Biomolecules & Therapeutics* (Seoul). 2014;22(s1):1-9.
50. Gupta S, Kapoor P, Chaudhary K. In silico approach for predicting toxicity of peptides and proteins. *PLoS One*. 2013;8(9):e73957.
51. Dimitrov I, Bangov I, Flower DR, Doytchinova I. AllerTOP v.2--a server for in silico prediction of allergens. *Journal of Molecular Modeling*. 2014;20(6):2278.
52. Sciani JM, Emerenciano AK, Cunha da Silva JR, Pimenta DC. Initial peptidomic profiling of Brazilian sea urchins: *Arbacia lixula*, *Lytechinus variegatus* and *Echinometra lucunter*. *Journal of Venomous Animals and Toxins including Tropical Diseases*. 2016;22:17.
53. Deka A, Saikia V. Prediction of ace-inhibitory and antioxidant peptides from storage proteins of edible seeds and nuts using in silico approaches. *Sustainable Food Proteins*. 2023;1(2):84–98.
54. Vijay GV, Zhao N, Den Hollander P, Toneff MJ, Joseph R, Pietila M, et al. GSK3 β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer. *Breast Cancer Research*. 2019 Mar 7;21(1):37.
55. Charpentier M, Martin S. Interplay of stem cell characteristics, EMT, and microtentacles in circulating breast tumor cells. *Cancers*. 2013;5(4):1545–65
56. Wu Y, Sarkissyan M, Vadgama JV. Epithelial-mesenchymal transition and breast cancer. *Journal of Clinical Medicine*. 2016;5(2):13.
57. Gao S, Li S, Duan X, Gu Z, Ma Z, Yuan X, Feng X, Wang H. Inhibition of glycogen synthase kinase 3 beta (GSK3 β) suppresses the progression of esophageal squamous cell carcinoma by modifying STAT3 activity. *Molecular Carcinogenesis*. 2017 Oct;56(10):2301-2316.
58. Sang X, Belmessabih N, Wang R, Stephen P, Lin SX. CRIF1-CDK2 Interface Inhibitors Enhance Taxol Inhibition of the Lethal Triple-Negative Breast Cancer. *Cancers* (Basel). 2022 Feb 16;14(4):989.
59. Singh U, Chashoo G, Khan SU, Mahajan P, Nargotra A, Mahajan G, et al. Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. *Journal of Medicinal Chemistry*. 2017 Dec 14;60(23):9470-9489.
60. Rao SS, Stoehr J, Dokic D, Wan L, Decker JT, Konopka K, et al. Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer. *Oncotarget*. 2017 Aug 10;8(48):83925-83939.
61. Zhu X, Zhou W. The Emerging Regulation of VEGFR-2 in Triple-Negative Breast Cancer. *Front Endocrinol* (Lausanne). 2015 Oct 9;6:159.
62. Behelgardji M.F., Zahri S., Shahvir Z.G., Mashayekhi F., Mirzanejad L., Asghari S.M. Targeting signaling pathways of VEGFR1 and VEGFR2 as a potential target in the treatment of breast cancer. *Molecular Biology Reports*. 2020;47:2061–2071.
63. Perrot-Appianat M., Di Benedetto M. Autocrine functions of VEGF in breast tumor cells. *Cell Adhesion & Migration*. 2013;6:547–553.

64. Yan JD, Liu Y, Zhang ZY, Liu GY, Xu JH, Liu LY, Hu YM. Expression, and prognostic significance of VEGFR-2 in breast cancer. *Pathology - Research and Practice*. 2015;211:539–543.
65. Wang X, Bove AM, Simone G, Ma B. Molecular Bases of VEGFR-2-Mediated Physiological Function and Pathological Role. *Frontiers in Cell and Developmental Biology*. 2020;8:599281.
66. Zhang J, Liu C, Shi W, Yang L, Zhang Q, Cui J, et al. The novel VEGF receptor 2 inhibitor YLL545 inhibits angiogenesis and growth in breast cancer. *Oncotarget*. 2016 Jul 5;7(27):41067-41080.
67. Gao Z, Shi M, Wang Y, Chen J, Ou Y. Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2. *Pathology - Research and Practice*. 2019 Jul;215(7):152422.

